【华福证券发布康方生物研报,看好自研双抗前景】8月11日,华福证券发布关于康方生物的研报。研报显示,该公司自研双抗AK112进度全球领先,有望占据全球二代IO市场最大份额。 研报预计,康方生物2025 - 2027年营业收入分别为35.18/57.65/93.72亿元,归母净利润分别为 - 1.86/8.03/29.66亿元。 此外,华福证券给出康方生物合理市值为2228亿港元,并维持买入评级。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.